Guangzhou Excelmabcloses multi-million-yuan Series A+ financing

Guangzhou Excelmab has completed tens of millions of yuan in A+ round of financing. The investors include Korea Investment Partners, CAS Investment Management, Mefine Capital, and Caijin Capital.

Guangzhou Excelmab has completed tens of millions of yuan in A+ round of financing. The investors include Korea Investment Partners, CAS Investment Management, Mefine Capital, and Caijin Capital.

The proceeds will be mainly used for the company’s research and development of dual-antibody drugs and the promotion of clinical trials for its dual-antibody innovative drugs for breast cancer.

Excelmab was established by Dr. Wenjun Zhang in 2016 in Guangzhou China. Excelmab takes it as its mission to improve patients’ life quality and promote human development.

With novel bispecific antibody platform, Excelmab has developed a series of anti-tumor bispecific antibody drugs, devoted to providing efficient and cost-effective drugs for cancer patients at home and abroad, and at the same time improving China’s innovation ability and technical level in biopharmaceutical field.

At present, Excelmab has developed EX101, a dual-antibody molecule targeting breast and gastric cancer with an internationally advanced level. The product is about to enter the preclinical experimental stage, and it is ready for IND submission at the end of this year.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/07/guangzhou-excelmabcloses-multi-million-yuan-series-a-financing/.

Leave a Reply

Please Login to Comment